Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia Meeting Spurs New Scrutiny Of FDA Conflict-Of-Interest Screening

Executive Summary

Revelations about speaking and consulting agreements between two FDA advisory committee members, Avandia maker GlaxoSmithKline and Actos maker Takeda, suggest the agency may need to further refine its conflict-of-interest screening procedures to ensure a public perception that it is receiving independent advice from outside experts

You may also be interested in...



FDA Policy On Financial Conflicts Of Public Speakers At Advisory Panels Unchanged

In final guidance, the agency has rejected calls by the advocacy group Public Citizen to allow committee members to question open public hearing speakers on their finances.

Avandia Advisory Committee Re-Review Reflects Well On FDA

The FDA advisory committee re-review of cardiovascular safety risks with GlaxoSmithKline's Avandia (rosiglitazone) will not end calls from agency critics to create a separate drug safety center. However, the transparency of internal scientific disputes on display at the July 13-14 meeting and the committee's recommendations could take some ammunition away from those who assert the Center for Drug Evaluation and Research has given short shrift to safety issues

FDA Casts Wide Net For Advice on Avandia

Agency increases number of voting members for the meeting of the Endocrinologic and Metabolic and Drug Safety and Risk Management Advisory Committees to 33, up 10 from 2007. Half of the committee's voting members also participated in the first review of rosiglitazone's postmarketing safety.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel